Beryl Drugs Limited has submitted its quarterly compliance filing to BSE Limited under Regulation 57(5) for the quarter ended 31st December, 2025. The pharmaceutical company, based in Indore, Madhya Pradesh, informed the stock exchange that the regulation provisions are not applicable to its operations during the reporting period.

Regulatory Compliance Filing Details

The compliance filing was submitted on 6th January, 2026, addressing the requirements under Regulation 57(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. The company's communication to BSE clarified its position regarding non-convertible securities obligations.

Non-Convertible Securities Position

Beryl Drugs Limited stated that Regulation 57(5) is not applicable to the company since there are no non-convertible securities for which interest, dividend, or principal payments are payable during the quarter ended 31st December, 2025. This indicates that the company does not currently have any outstanding non-convertible debentures or similar debt instruments that would require compliance reporting under this specific regulation.

Company Information and Authorization

The filing was authorized and signed by Sudhir Sethi, Chairman & Director of Beryl Drugs Limited, bearing Director Identification Number (DIN) 00090172. The company operates from its registered office located at Ground Floor, 133, Kanchan Bagh, Indore - 452001, Madhya Pradesh.

This compliance filing represents a routine regulatory requirement for listed companies to inform stock exchanges about their obligations under various SEBI regulations, ensuring transparency in corporate governance and investor protection.

Beryl Drugs Limited announced significant board appointments through an official disclosure to BSE Limited under Regulation 30 of SEBI (LODR) Regulations 2015. The appointments were approved during the board meeting held on January 3, 2026, at the company's registered office in Indore, based on recommendations from the Nomination and Remuneration Committee.

Director Appointments and Regulatory Compliance

The board approved two key director appointments requiring shareholder approval at the upcoming general meeting. Mr. Shailendra Pathak (DIN: 11169772) was appointed as Additional Director to be regularized as Whole Time Director, while Mrs. Neha Sarda (DIN: 08456141) was designated as Independent Director (Non-Executive). The company confirmed that both appointees are not debarred from holding director positions by SEBI or any other regulatory authority.

Professional Background and Expertise

Mr. Shailendra Pathak brings four decades of experience with his diploma in electrical engineering. He currently serves as a director in Aminova Infusions Private Limited and maintains no relationships with existing directors or key managerial personnel of the company. His extensive experience positions him well for the whole-time director role.

Mrs. Neha Sarda is a qualified Company Secretary and holds an M.COM degree. As a member of the Institute of Company Secretaries of India (ICSI), she brings 14 years of specialized experience in finance and compliance management. Her expertise aligns with the independent director requirements for corporate governance oversight.

Regulatory Disclosure Requirements

The appointments comply with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, regarding director appointment disclosures. The company provided comprehensive details including professional qualifications, experience, inter-se relationships, and existing directorships as mandated under Schedule III of the Listing Regulations.

Corporate Governance Enhancement

The board changes reflect Beryl Drugs' commitment to strengthening corporate governance with experienced professionals in operational and oversight roles. Both appointments are subject to shareholder approval in the ensuing general meeting, ensuring proper corporate governance procedures are followed. The company also addressed related party transactions with Aminova Infusions Private Limited, requiring similar shareholder consent.

The appointments demonstrate the company's focus on bringing diverse expertise to the board, combining operational experience through the whole-time director appointment and governance oversight through the independent director position.